Experienced in Follicular Lymphoma

Dr. Jack J. Hsu

Hematology | Oncology
North Florida Surgical Associates LLC
6400 W Newberry Rd, Suite 202, 
Gainesville, FL 
Accepting New Patients
Experienced in Follicular Lymphoma
North Florida Surgical Associates LLC
6400 W Newberry Rd, Suite 202, 
Gainesville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jack Hsu is a Hematologist and an Oncologist in Gainesville, Florida. Dr. Hsu is rated as an Experienced provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Acute Myeloid Leukemia (AML), Multiple Myeloma, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Hsu is currently accepting new patients.

His clinical research consists of co-authoring 63 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Follicular Lymphoma.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in NJ
Hospital Affiliations
Hca Florida North Florida Hospital
Languages Spoken
English
Italian
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

NORTH FLORIDA SURGICAL ASSOCIATES LLC
6400 W Newberry Rd, Suite 202, Gainesville, FL 32605

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) in Complete Remission
Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) in Complete Remission
Enrollment Status: Terminated
Publish Date: January 16, 2025
Intervention Type: Drug
Study Drug: Cytarabine
Study Phase: Phase 2
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
Enrollment Status: Terminated
Publish Date: July 15, 2024
Intervention Type: Drug
Study Drugs: ONO-7475, Venetoclax
Study Phase: Phase 1/Phase 2
Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That is Refractory to or Relapsed After Standard Induction Therapy
Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That is Refractory to or Relapsed After Standard Induction Therapy
Enrollment Status: Completed
Publish Date: March 10, 2022
Intervention Type: Drug
Study Drug: Liposomal Annamycin
Study Phase: Phase 1/Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: September 27, 2018
Intervention Type: Biological
Study Phase: Phase 2
View 5 Less Clinical Trials

63 Total Publications

Soluble B-cell maturation antigen as a serum marker of MRD in patients with multiple myeloma.
Soluble B-cell maturation antigen as a serum marker of MRD in patients with multiple myeloma.
Journal: Frontiers in oncology
Published: May 19, 2025
Similar Doctors
Distinguished in Follicular Lymphoma
Dr. Nam H. Dang
Oncology | Hematology Oncology
Distinguished in Follicular Lymphoma
Dr. Nam H. Dang
Oncology | Hematology Oncology
1600 Sw Archer Rd, 
Gainesville, FL 
 (4.4 miles away)
352-273-7832
Languages Spoken:
English
See accepted insurances

Nam Dang is an Oncologist and a Hematologist Oncology provider in Gainesville, Florida. Dr. Dang is rated as a Distinguished provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Large-Cell Immunoblastic Lymphoma.

Advanced in Follicular Lymphoma
Dr. James W. Lynch
Oncology
Advanced in Follicular Lymphoma
Dr. James W. Lynch
Oncology

Florida Clinical Practice Association Inc

2001 Sw 13th St, Gi Clinic At Endoscopy Cen, 
Gainesville, FL 
 (4.8 miles away)
352-265-8982
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Lynch is an Oncologist in Gainesville, Florida. Dr. Lynch is rated as a Distinguished provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Gastric Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Large-Cell Immunoblastic Lymphoma. Dr. Lynch is currently accepting new patients.

Distinguished in Follicular Lymphoma
Dr. Avani A. Changela
Hematology Oncology | Hematology | Oncology
Distinguished in Follicular Lymphoma
Dr. Avani A. Changela
Hematology Oncology | Hematology | Oncology

Baptist MD Anderson Cancer Physicians Inc

14546 Old Saint Augustine Rd, Suite 100, 
Jacksonville, FL 
 (62.1 miles away)
904-202-7300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Avani Changela is a Hematologist Oncology specialist and a Hematologist in Jacksonville, Florida. Dr. Changela is rated as a Distinguished provider by MediFind in the treatment of Follicular Lymphoma. Her top areas of expertise are Familial Colorectal Cancer, Monoclonal Gammopathy of Undetermined Significance (MGUS), Colorectal Cancer, and Follicular Lymphoma. Dr. Changela is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hsu's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 13 Advanced Conditions
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile